Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Nonpregnant Women And Pregnant Women And Their Infants
Group B Streptococcus Infections
Bottom Line
View on ClinicalTrials.gov: NCT03765073 ↗Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Multivalent Group B streptococcus vaccine (Biological); Placebo (Biological)
- Age
- Pediatric, Adult · 0+ yrs
- Sex
- All
- Sponsor
- Pfizer
- Primary completion
- Mar 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Reporting Local Reactions Within 7 Days After Primary Dose: Non-Pregnant Participants Stage 1 |
27.3; 27.3; 13.6; 22.7; 13.6; 9.1 | — |
| PRIMARY Percentage of Participants Reporting Local Reactions Within 7 Days After Booster Dose: Non-Pregnant Women Stage 1 |
72.7; 28.6; 50.0; 45.5; 28.6; 37.5 | — |
| PRIMARY Percentage of Participants Reporting Systemic Events Within 7 Days After Primary Dose: Non-Pregnant Participants Stage 1 |
0; 4.5; 0; 0; 0; 0 | — |
| PRIMARY Percentage of Participants Reporting Systemic Events Within 7 Days After Booster Dose: Non-Pregnant Participants Stage 1 |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Percentage of Participants Reporting Adverse Events (AEs) Through 1 Month After Primary Dose: Non-Pregnant Participants Stage 1 |
54.5; 45.5; 36.4 | — |
| PRIMARY Percentage of Participants Reporting AEs Through 1 Month After Booster Dose: Non-Pregnant Participants Stage 1 |
18.2; 0; 12.5 | — |
| PRIMARY Percentage of Participants Reporting Medically Attended Adverse Events (MAEs) Through 6 Months After Primary Dose: Non-Pregnant Participants Stage 1 |
45.5; 40.9; 40.9 | — |
| PRIMARY Percentage of Participants Reporting Serious Adverse Events (SAEs) Through 6 Months After Primary Dose: Non-Pregnant Participants Stage 1 |
0; 0; 0 | — |
| PRIMARY Percentage of Participants Reporting MAEs Approximately 7 to 12 Months After Booster Dose: Non-Pregnant Participants Stage 1 |
0; 14.3; 25.0 | — |
| PRIMARY Percentage of Participants Reporting SAEs Approximately 7 to 12 Months After Booster Dose: Non-Pregnant Participants Stage 1 |
0; 0; 0 | — |
| PRIMARY Number of Participants With Clinical Laboratory Abnormalities at 2 Week Follow-up Visit: Maternal Participants Stage 2 |
0; 7.1; 0; 7.1; 0; 0 | — |
| PRIMARY Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination: Maternal Participants Stage 2 |
37.5; 15.0; 40.0; 15.4; 47.5; 35.0 | — |
| PRIMARY Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination: Maternal Participants Stage 3 |
30.2; 18.4; 25.5; 13.6; 4.7; 4.9 | — |
| PRIMARY Percentage of Participants Reporting Systemic Events Within 7 Days Following Administration of Investigational Product: Maternal Participants Stage 2 |
2.5; 5.0; 2.5; 7.7; 2.5; 5.0 | — |
| PRIMARY Percentage of Participants Reporting Systemic Events Within 7 Days Following Administration of Investigational Product: Maternal Participants Stage 3 |
2.8; 4.9; 2.8; 2.9; 0; 1.9 | — |
| PRIMARY Percentage of Participants Reporting AEs Through 1 Month After Administration of Investigational Product: Maternal Participants Stage 2 |
27.5; 40.0; 22.5; 22.5; 30.0; 30.0 | — |
| PRIMARY Percentage of Participants Reporting AEs Through 1 Month After Administration of Investigational Product: Maternal Participants Stage 3 |
36.1; 32.4 | — |
| PRIMARY Percentage of Participants With SAEs From Day 1 Through 12 Months Post-delivery: Maternal Participants Stage 2 |
17.5; 45.0; 22.5; 27.5; 20.0; 35.0 | — |
| PRIMARY Percentage of Participants With SAEs From Day 1 Through 12 Months Post-delivery: Maternal Participants Stage 3 |
19.4; 21.3 | — |
| PRIMARY Percentage of Participants With MAEs From Day 1 Through 12 Months Post-delivery: Maternal Participants Stage 2 |
30.0; 45.0; 30.0; 27.5; 25.0; 32.5 | — |
| PRIMARY Percentage of Participants With MAEs From Day 1 Through 12 Months Post-delivery: Maternal Participants Stage 3 |
51.9; 42.6 | — |
| PRIMARY Percentage of Participants With Obstetric Complications From Visit 1 Through 12 Months Post-delivery: Maternal Participants Stage 2 |
5.0; 12.5; 5.0; 10.0; 5.0; 10.0 | — |
| PRIMARY Percentage of Participants With Obstetric Complications From Day 1 Through 12 Months Post-delivery: Maternal Participants Stage 3 |
9.3; 13.0; 13.9; 13.0; 2.8; 1.9 | — |
| PRIMARY Percentage of Participants With Each Delivery Outcome and Delivery Mode: Maternal Participants Stage 2 |
92.5; 90.0; 97.5; 100.0; 97.5; 97.5 | — |
| PRIMARY Percentage of Participants With Each Delivery Outcome and Delivery Mode: Maternal Participants Stage 3 |
88.0; 91.7; 7.4; 5.6; 0.9; 0 | — |
| PRIMARY Percentage of Participants With Gestational Age at Birth: Infant Participants Stage 2 |
0; 0; 0; 0; 0; 0 | — |
| PRIMARY Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute: Infant Participants Stage 2 |
9.0; 9.0; 9.0; 9.0; 9.0; 9.0 | — |
| PRIMARY Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 5 Minutes: Infant Participants Stage 2 |
10.0; 10.0; 10.0; 10.0; 10.0; 10.0 | — |
| PRIMARY Number of Participants According to Age Determined by Ballard Score: Infant Participants Stage 2 |
1; 2; 1; 1; 2; 2 | — |
| PRIMARY Number of Participants With Newborn Assessment at Birth: Infant Participants Stage 2 |
34; 30; 38; 38; 34; 35 | — |
| PRIMARY Number of Participants With Vital Status: Infant Participants Stage 2 |
40; 38; 40; 40; 40; 40 | — |
| PRIMARY Number of Participants With Gestational Age of Participants at Birth: Infant Participants Stage 3 |
0; 0; 1; 2; 7; 4 | — |
| PRIMARY Appearance, Pulse, Grimace, Activity, and Respiration (APGAR) Score at 1 Minute: Infant Participants Stage 3 |
9.0; 9.0 | — |
| PRIMARY APGAR Score at 5 Minutes: Infant Participants Stage 3 |
10.0; 10.0 | — |
| PRIMARY Number of Participants According to Age Determined by Ballard Score: Infant Participants Stage 3 |
4; 4; 30; 37; 5; 4 | — |
| PRIMARY Number of Participants With Newborn Assessment at Birth: Infant Participants Stage 3 |
82; 79; 15; 16; 12; 15 | — |
| PRIMARY Number of Participants With Vital Status: Infant Participants Stage 3 |
103; 104; 1; 1 | — |
| PRIMARY Number of Participants With AEs From Birth to 6 Weeks of Age: Infant Participants Stage 2 |
26; 21; 25; 21; 19; 18 | — |
| PRIMARY Numberof Participants With AEs From Birth to 6 Weeks of Age: Infant Participants Stage 3 |
65; 64 | — |
| PRIMARY Number of Participants With SAEs From Birth to 12 Months of Age: Infant Participants Stage 2 |
17; 19; 15; 12; 19; 14 | — |
| PRIMARY Number of Participants With SAEs From Birth to 12 Months of Age: Infant Participants Stage 3 |
45; 46 | — |
| PRIMARY Number of Participants With MAEs From Birth to 12 Months of Age: Infant Participants Stage 2 |
22; 14; 19; 21; 18; 18 | — |
| PRIMARY Number of Participants With MAEs From Birth to 12 Months of Age: Infant Participants Stage 3 |
65; 66 | — |
| PRIMARY Percentage of Participants With Adverse Events of Special Interest From Birth to 12 Months of Age: Infant Participants Stage 2 |
0; 2.6; 2.5; 0; 0; 0 | — |
| PRIMARY Percentage of Participants With Adverse Events of Special Interest From Birth to 12 Months of Age: Infant Participants Stage 3 |
0; 0; 1.0; 0; 0; 0 | — |
| SECONDARY Geometric Mean Concentration (GMCs) of Group B Streptococcus (GBS) Serotype-Specific Immunoglobulin G (IgG) at 1 Month After Primary Dose: Non-Pregnant Women Stage 1 |
64.729; 25.781; 0.152; 4.986; 5.546; 0.019 | — |
| SECONDARY GMCs of GBS Serotype-specific IgG Before and 1 Month, 3 Months, and 6 Months After a Booster Dose: Non Pregnant Women Stage 1 |
21.088; 3.230; 0.812; 86.661; 48.241; 68.222 | — |
| SECONDARY GMCs of GBS Serotype-specific IgG at 2 Weeks, 1 Month After Vaccination and at Delivery: Maternal Participants Stage 2 |
8.399; 16.089; 11.073; 10.782; 13.813; 41.201 | — |
| SECONDARY GMCs of GBS Serotype-specific IgG at 2 Weeks, 1 Month After Vaccination and at Delivery: Maternal Participants Stage 3 |
9.233; 0.051; 9.631; 0.054; 8.817; 0.052 | — |
| SECONDARY GBS6 Serotype-Specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination and at Delivery: Maternal Participants Stage 2 |
13012.1; 7765.3; 14408.2; 9722.0; 8133.8; 23271.2 | — |
| SECONDARY GBS6 Serotype-Specific OPA Geometric Mean Titers (GMTs) at 1 Month After Vaccination and at Delivery: Maternal Participants Stage 3 |
11462.9; 196.1; 6228.2; 211.4; 13306.1; 480.8 | — |
| SECONDARY GMCs of GBS6 Serotype-Specific IgG Infant Participant at Birth: Infant Participants Stage 2 |
4.322; 10.978; 6.128; 11.089; 6.094; 22.159 | — |
| SECONDARY GMCs of GBS6 Serotype-Specific IgG Infant Participant at Birth: Infant Participants Stage 3 |
6.366; 0.048; 0.466; 0.009; 16.123; 0.134 | — |
| SECONDARY GBS6 Serotype-Specific OPA GMTs Measured at Birth: Infant Participants Stage 2 |
991.5; 2116.3; 1927.4; 3053.1; 1459.1; 7916.5 | — |
| SECONDARY GBS6 Serotype-Specific OPA GMTs Measured at Birth: Infant Participants Stage 3 |
1173.7; 89.5; 1108.3; 114.8; 3639.4; 291.0 | — |
Summary
Eligibility Criteria
Inclusion Criteria Stage 1 Nonpregnant Women:
- Healthy nonpregnant females 18 to 40 years of age at enrollment who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
- Negative urine pregnancy test at Visit 1 (prior to vaccination).
- Documented negative HIV, hepatitis C virus (HCV), and acute or chronic hepatitis B virus (HBV) infection at screening.
Inclusion Criteria Stage 1 Booster Vaccination:
- Participant must have received investigational product at Visit 1.
- Healthy nonpregnant female determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for booster vaccination and received investigational product at Visit 1.
- Negative urine pregnancy test at Visit 6 (prior to vaccination).
- Documented negative HIV, hepatitis C virus (HCV), and acute or chronic hepatitis B virus (HBV) infection at screening.
Inclusion Criteria Stage 2 and 3 Maternal Participants:
- Healthy females >=18 and =27 0/7 (Stage 2) or >=24 0/7 (Stage 3) to <=35 6/7 weeks' gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, and at no increased risk for complications and no significant fetal abnormalities observed on ultrasound performed at any time prior to study entry and/or at the screening visit.
- Documented negative HIV antibody, HBV surface antigen, HCV antibody, and syphilis tests at screening.
Inclusion Criteria Stage 2 and 3 Infant Participants:
Evidence of a signed and dated ICD signed by the parent(s). Parent(s) willing and able to comply with scheduled visits, investigational plan, laboratory tests, and other study procedures.
Exclusion Criteria Stage 1 Nonpregnant Women:
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product or any diphtheria toxoid-containing or CRM197 containing vaccine.
- History of microbiologically proven invasive disease caused by GBS (S agalactiae).
- Previous vaccination with any licensed or investigational GBS vaccine (other than GBS6 received as a primary vaccination at Visit 1), or planned receipt during the participant's participation in the study (through the last blood draw).
Exclusion criteria Stage 2 and 3 Maternal Participants:
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product or any diphtheria toxoid-containing or CRM197 containing vaccine.
- History of microbiologically proven invasive disease caused by GBS (S agalactiae).
- Previous vaccination with any licensed or investigational group B streptococcus vaccine, or planned receipt during the participant's participation in the study (through the last blood draw).
- Prepregnancy body mass index (BMI) of ≥40 kg/m2. If prepregnancy BMI is not available, the BMI at the time of the first obstetric visit during the current pregnancy may be used.
- A prior history of or current pregnancy complications or abnormalities that will increase t
Data sourced from ClinicalTrials.gov (NCT03765073). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.